iShares Biotechnology ETF
853 hedge funds and large institutions have $8.89B invested in iShares Biotechnology ETF in 2020 Q4 according to their latest regulatory filings, with 142 funds opening new positions, 263 increasing their positions, 270 reducing their positions, and 58 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more ownership
Funds ownership: →
3% less repeat investments, than reductions
Existing positions increased: 263 | Existing positions reduced: 270
12% less funds holding in top 10
Funds holding in top 10: 17 → 15 (-2)
46% less call options, than puts
Call options by funds: $818M | Put options by funds: $1.5B
Holders
853
Holding in Top 10
15
Calls
$818M
Puts
$1.5B
Top Buyers
1 | +$682M | |
2 | +$399M | |
3 | +$167M | |
4 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
+$151M |
5 |
Citigroup
New York
|
+$60.5M |
Top Sellers
1 | -$415M | |
2 | -$238M | |
3 | -$106M | |
4 |
N
Natixis
Paris,
France
|
-$67.7M |
5 |
Squarepoint
New York
|
-$29.3M |